TABLE 4.

Propensity Score Weight-Adjusted ORs and Associated 95% CIs from Logistic Regression Models,^a Persistence (Defined with 30- and 90-Day Gap Allowances) with Index Therapy over 12 Months

	Persistence (30-Day Gap Allowance)	95% CI		Persistence (90-Day Gap Allowance)	95% CI
	OR	Lower	Upper	OR	Lower	Upper
Denosumab vs. alendronate	5.10	4.48	5.85	4.00	3.48	4.61
Denosumab vs. ibandronate	5.68	4.81	6.67	3.82	3.25	4.48
Denosumab vs. risedronate	6.67	5.56	7.94	5.32	4.48	6.33
Denosumab vs. raloxifene	3.18	2.64	3.85	2.87	2.37	3.46
Denosumab vs. teriparatide	1.83	1.43	2.35	1.15	1.16	1.96

^aModels adjusted for age, health plan type, U.S. Census region, urban residency, patient out-of-pocket expenditure for the index therapy, and the following baseline/preindex clinical characteristics: Charlson Comorbidity Index score; number of unique medications prescribed; and diagnosis of osteoporosis, osteopenia, renal insufficiency, gastrointestinal disorders, coronary heart disease, and osteoporosis-related fracture.

CI = confidence interval; OR = odds ratio.